Format
Sort by

Send to

Choose Destination

Search results

Items: 7

1.

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J.

Pediatrics. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479.

PMID:
27335380
2.

Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine.

Cao JM, Ma JD, Morello CM, Atayee RS, Best BM.

J Opioid Manag. 2014 May-Jun;10(3):177-86. doi: 10.5055/jom.2014.0206.

PMID:
24944068
3.

Urinary hydrocodone and metabolite distributions in pain patients.

Barakat NH, Atayee RS, Best BM, Ma JD.

J Anal Toxicol. 2014 Sep;38(7):404-9. doi: 10.1093/jat/bku051.

PMID:
24836897
4.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium..

Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Review.

5.

Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.

Madadi P, Hildebrandt D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJ, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G.

Pediatrics. 2010 Oct;126(4):e986-9. doi: 10.1542/peds.2009-1907.

PMID:
20837591
6.

Maternal-fetal and neonatal pharmacogenomics: a review of current literature.

Blumenfeld YJ, Reynolds-May MF, Altman RB, El-Sayed YY.

J Perinatol. 2010 Sep;30(9):571-9. doi: 10.1038/jp.2009.183. Review.

7.

The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.

Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA.

J Pediatr. 2007 Jun;150(6):623-6.

Items per page

Supplemental Content

Loading ...
Support Center